However, more recently, a phase I trial (NCT04214860) has shown that the addition of APR-246 to VEN and AZA appears encouraging in treating TP53-mutated AML with a well-tolerated toxicity profile and promising efficacy by achieving an overall response of 64% (25/49) and a CR of 38% (15/39) [137]. The gene discussed is TP53; the disease is acute myeloid leukemia.